CA3011870A1 - Proteinaceous compounds and uses therefor - Google Patents

Proteinaceous compounds and uses therefor Download PDF

Info

Publication number
CA3011870A1
CA3011870A1 CA3011870A CA3011870A CA3011870A1 CA 3011870 A1 CA3011870 A1 CA 3011870A1 CA 3011870 A CA3011870 A CA 3011870A CA 3011870 A CA3011870 A CA 3011870A CA 3011870 A1 CA3011870 A1 CA 3011870A1
Authority
CA
Canada
Prior art keywords
amino acid
proteinaceous molecule
pkc
cell
modified forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3011870A
Other languages
English (en)
French (fr)
Inventor
Sudha RAO
Peter MILBURN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Canberra
Original Assignee
University of Canberra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900314A external-priority patent/AU2016900314A0/en
Application filed by University of Canberra filed Critical University of Canberra
Publication of CA3011870A1 publication Critical patent/CA3011870A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3011870A 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor Abandoned CA3011870A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016900314 2016-02-01
AU2016900314A AU2016900314A0 (en) 2016-02-01 Proteinaceous compounds and uses therefor
PCT/AU2017/050083 WO2017132728A1 (en) 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor

Publications (1)

Publication Number Publication Date
CA3011870A1 true CA3011870A1 (en) 2017-08-10

Family

ID=59499146

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3011870A Abandoned CA3011870A1 (en) 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor

Country Status (8)

Country Link
US (1) US10487115B2 (https=)
EP (1) EP3411061A4 (https=)
JP (2) JP7341451B2 (https=)
CN (2) CN116082457A (https=)
AU (1) AU2017214761B2 (https=)
CA (1) CA3011870A1 (https=)
SG (1) SG11201806122YA (https=)
WO (1) WO2017132728A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090390A1 (en) * 2017-11-08 2019-05-16 University Of Canberra Immunogenic compositions and uses therefor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5976567A (en) 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
AUPP807899A0 (en) 1999-01-08 1999-02-04 University Of Queensland, The Codon utilization
WO2000036083A2 (en) * 1998-12-17 2000-06-22 La Jolla Institute For Allergy And Immunology Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methods of making and using them
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
AU2000265054A1 (en) 2000-07-31 2002-02-13 Dabur Research Foundation Lipid-peptide conjugates for treatment of cancer
CA2489458A1 (en) 2002-06-14 2003-12-24 Altana Pharma Ag Substituted diaminopyrimidines
WO2004076654A1 (en) * 2003-02-28 2004-09-10 Novartis Ag Three-dimensional structure of the catalytic domain of protein c theta, methods and use thereof
US9592277B2 (en) 2004-04-14 2017-03-14 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
KR100859972B1 (ko) 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
US11311610B2 (en) * 2010-11-01 2022-04-26 University Of Technology Sydney Immune-modulating agents and uses therefor
EP3384939A1 (en) * 2011-03-11 2018-10-10 Vib Vzw Molecules and methods for inhibition and detection of proteins
CA2885894C (en) 2012-09-27 2021-11-23 University Of British Columbia Peptide directed protein knockdown
ES2851724T3 (es) 2013-09-18 2021-09-08 Epiaxis Therapeutics Pty Ltd Modulación de células madre
CA2958704A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor

Also Published As

Publication number Publication date
CN108883155A (zh) 2018-11-23
JP7341451B2 (ja) 2023-09-11
EP3411061A4 (en) 2019-07-10
AU2017214761A1 (en) 2018-08-02
US10487115B2 (en) 2019-11-26
JP2022023949A (ja) 2022-02-08
AU2017214761B2 (en) 2024-02-01
SG11201806122YA (en) 2018-08-30
CN116082457A (zh) 2023-05-09
EP3411061A1 (en) 2018-12-12
US20190040103A1 (en) 2019-02-07
JP2019506167A (ja) 2019-03-07
WO2017132728A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
AU2019207534B2 (en) Proteinaceous molecules and uses therefor
AU2006291541B2 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1895005B1 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7662786B2 (en) Dolastatin 15 derivatives
MX2011004019A (es) Conjugados de etoposido y doxorubicina para entrega de farmacos.
US20220315631A1 (en) Stapled beta-catenin ligands
CN106659764B (zh) 环状鞘脂激活蛋白原肽及其用途
CN102140473A (zh) 抗肿瘤的核酸与多肽及其应用
AU2017214761B2 (en) Proteinaceous compounds and uses therefor
US8440788B2 (en) N-terminal VDAC variants and uses thereof
WO2014022271A1 (en) Method of treating metastatic cancer
KR100409264B1 (ko) 세포내 신호전달을 교란시키는 합성 펩티드
WO2014034922A1 (ja) 血管内皮細胞増殖因子受容体阻害ペプチド
US20240228543A1 (en) Cyclic peptide inhibitors of usp22
KR20250138134A (ko) 표적 단백질 분해자 및 세포 투과 펩타이드를 포함하는 융합 분자 및 이의 용도
WO2026071086A1 (ja) ペプチド、ペプチド複合体、細胞培養用組成物、医療用、診断用又は研究用に用いられる組成物、及びペプチド複合体の製造方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211118

FZDE Discontinued

Effective date: 20240501